Literature DB >> 22487732

Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression.

Julien Mendlewicz1, Concetta Crisafulli, Raffaella Calati, Neslihan Aygun Kocabas, Isabelle Massat, Sylvie Linotte, Siegfried Kasper, Martin Fink, Antonina Sidoti, Gabrielle Scantamburlo, Marc Ansseau, Irina Antonijevic, Carlos Forray, Lenore Snyder, Joseph Bollen, Stuart Montgomery, Joseph Zohar, Daniel Souery, Alessandro Serretti.   

Abstract

Inflammatory pathways play a crucial role in the pathomechanisms of antidepressant efficacy. The aim of this study was to investigate whether a set of single nucleotide polymorphisms (SNPs) within cyclooxygenase-2 (COX-2, rs5275 and rs20417) and oxytocin receptor (OXTR, rs53576 and rs2254298) genes was associated with antidepressant treatment resistance, response or remission. Three hundred seventy-two patients were recruited in the context of a multicenter resistant depression study. They were genotyped for COX-2 and OXTR SNPs. Treatment resistance (according to two different definitions), response and remission were recorded. We did not observe any association between the genotypes or alleles of the selected SNPs within COX-2 and OXTR genes and treatment resistance, response and remission in the whole sample. Our results are consistent with those of some studies but not with those of other ones. Indeed, several factors could be involved in the discrepancy observed across studies. They include sample size, environmental factors, differences in ethnicity, different study designs, and different definitions of treatment resistance.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22487732     DOI: 10.1016/j.neulet.2012.03.063

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  Feasibility of an interval, inspiration-triggered nocturnal odorant application by a novel device: a patient-blinded, randomised crossover, pilot trial on mood and sleep quality of depressed female inpatients.

Authors:  Frank Vitinius; Martin Hellmich; Annalena Matthies; Fabian Bornkessel; Heiner Burghart; Christian Albus; Karl-Bernd Huettenbrink; Julia Vent
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-05       Impact factor: 2.503

2.  The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.

Authors:  Peter Höfer; Alexandra Schosser; Raffaella Calati; Alessandro Serretti; Isabelle Massat; Neslihan Aygun Kocabas; Anastasios Konstantinidis; Sylvie Linotte; Julien Mendlewicz; Daniel Souery; Joseph Zohar; Alzbeta Juven-Wetzler; Stuart Montgomery; Siegfried Kasper
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-10-19       Impact factor: 5.270

Review 3.  Oxytocin and Vasopressin Receptor Gene Polymorphisms: Role in Social and Psychiatric Traits.

Authors:  Mauricio Aspé-Sánchez; Macarena Moreno; Maria Ignacia Rivera; Alejandra Rossi; John Ewer
Journal:  Front Neurosci       Date:  2016-01-28       Impact factor: 4.677

Review 4.  Genetic Contributions of Inflammation to Depression.

Authors:  Jacob Barnes; Valeria Mondelli; Carmine M Pariante
Journal:  Neuropsychopharmacology       Date:  2016-08-24       Impact factor: 7.853

5.  Novel association between TGFA, TGFB1, IRF1, PTGS2 and IKBKB single-nucleotide polymorphisms and occurrence, severity and treatment response of major depressive disorder.

Authors:  Katarzyna Bialek; Piotr Czarny; Cezary Watala; Paulina Wigner; Monika Talarowska; Piotr Galecki; Janusz Szemraj; Tomasz Sliwinski
Journal:  PeerJ       Date:  2020-02-25       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.